Our current data suggest that, as an alternative to NSAIDs and as a novel approach for treating neuroinflammation, manipulating PGD2 signaling with, for example, DP2 receptor antagonists, could have a significant translational and multifactorial potential as a therapeutic for AD. The gene discussed is PTGDS; the disease is Alzheimer disease.